SLC2A1 and cancer: WZB117 inhibits GLUT‐1 as shown via [3H]2DG uptake inhibition in red blood cells (which express solely GLUT‐1).17b Although WZB117 has been used as GLUT‐1‐selective inhibitor in multiple studies mostly focusing on cancer,18 it was proposed to inhibit mainly GLUT‐4 as determined by GLUT‐1‐, ‐3‐, and ‐4‐overexpressing HEK293 cells ([3H]2DG uptake, Table 2).12b Kinetic studies revealed a competitive inhibition of glucose uptake.12b